In adults with T2D and clinical ASCVD, who use SGLT2i or GLP-1 RA, and HbA1c is still above the target, dual therapy with 2 AD1 SHOULD BE CONSIDERED to improve glycemic control. This evidence concerns the gene GCG and atherosclerosis.